160 related articles for article (PubMed ID: 12644838)
1. IDN 5390: an oral taxane candidate for protracted treatment schedules.
Pratesi G; Laccabue D; Lanzi C; Cassinelli G; Supino R; Zucchetti M; Frapolli R; D'Incalci M; Bombardelli E; Morazzoni P; Riva A; Zunino F
Br J Cancer; 2003 Mar; 88(6):965-72. PubMed ID: 12644838
[TBL] [Abstract][Full Text] [Related]
2. Antitumour and antiangiogenic effects of IDN 5390, a novel C-seco taxane, in a paclitaxel-resistant human ovarian tumour xenograft.
Petrangolini G; Cassinelli G; Pratesi G; Tortoreto M; Favini E; Supino R; Lanzi C; Belluco S; Zunino F
Br J Cancer; 2004 Apr; 90(7):1464-8. PubMed ID: 15054472
[TBL] [Abstract][Full Text] [Related]
3. Effects of orally active taxanes on P-glycoprotein modulation and colon and breast carcinoma drug resistance.
Vredenburg MR; Ojima I; Veith J; Pera P; Kee K; Cabral F; Sharma A; Kanter P; Greco WR; Bernacki RJ
J Natl Cancer Inst; 2001 Aug; 93(16):1234-45. PubMed ID: 11504769
[TBL] [Abstract][Full Text] [Related]
4. Antiangiogenic and antitumor activity of IDN 5390, a new taxane derivative.
Taraboletti G; Micheletti G; Rieppi M; Poli M; Turatto M; Rossi C; Borsotti P; Roccabianca P; Scanziani E; Nicoletti MI; Bombardelli E; Morazzoni P; Riva A; Giavazzi R
Clin Cancer Res; 2002 Apr; 8(4):1182-8. PubMed ID: 11948131
[TBL] [Abstract][Full Text] [Related]
5. Oral efficacy and bioavailability of a novel taxane.
Polizzi D; Pratesi G; Monestiroli S; Tortoreto M; Zunino F; Bombardelli E; Riva A; Morazzoni P; Colombo T; D'Incalci M; Zucchetti M
Clin Cancer Res; 2000 May; 6(5):2070-4. PubMed ID: 10815934
[TBL] [Abstract][Full Text] [Related]
6. IDN 5390: a new concept in taxane development.
Taraboletti G; Micheletti G; Giavazzi R; Riva A
Anticancer Drugs; 2003 Apr; 14(4):255-8. PubMed ID: 12679728
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and metabolism in mice of IDN 5390 (13-(N-Boc-3-i-butylisoserinoyl)-C-7,8-seco-10-deacetylbaccatin III), a new oral c-seco-taxane derivative with antiangiogenic property effective on paclitaxel-resistant tumors.
Frapolli R; Marangon E; Zaffaroni M; Colombo T; Falcioni C; Bagnati R; Simone M; D'Incalci M; Manzotti C; Fontana G; Morazzoni P; Zucchetti M
Drug Metab Dispos; 2006 Dec; 34(12):2028-35. PubMed ID: 16963486
[TBL] [Abstract][Full Text] [Related]
8. Cellular bases of the antitumor activity of the novel taxane IDN 5109 (BAY59-8862) on hormone-refractory prostate cancer.
Cassinelli G; Lanzi C; Supino R; Pratesi G; Zuco V; Laccabue D; Cuccuru G; Bombardelli E; Zunino F
Clin Cancer Res; 2002 Aug; 8(8):2647-54. PubMed ID: 12171897
[TBL] [Abstract][Full Text] [Related]
9. A role for loss of p53 function in sensitivity of ovarian carcinoma cells to taxanes.
Cassinelli G; Supino R; Perego P; Polizzi D; Lanzi C; Pratesi G; Zunino F
Int J Cancer; 2001 Jun; 92(5):738-47. PubMed ID: 11340581
[TBL] [Abstract][Full Text] [Related]
10. Antitumor efficacy of taxane liposomes on a human ovarian tumor xenograft in nude athymic mice.
Sharma A; Straubinger RM; Ojima I; Bernacki RJ
J Pharm Sci; 1995 Dec; 84(12):1400-4. PubMed ID: 8748320
[TBL] [Abstract][Full Text] [Related]
11. A novel taxane with improved tolerability and therapeutic activity in a panel of human tumor xenografts.
Polizzi D; Pratesi G; Tortoreto M; Supino R; Riva A; Bombardelli E; Zunino F
Cancer Res; 1999 Mar; 59(5):1036-40. PubMed ID: 10070960
[TBL] [Abstract][Full Text] [Related]
12. IDN5109, a taxane with oral bioavailability and potent antitumor activity.
Nicoletti MI; Colombo T; Rossi C; Monardo C; Stura S; Zucchetti M; Riva A; Morazzoni P; Donati MB; Bombardelli E; D'Incalci M; Giavazzi R
Cancer Res; 2000 Feb; 60(4):842-6. PubMed ID: 10706091
[TBL] [Abstract][Full Text] [Related]
13. Preclinical oral antitumor activity of BMS-185660, a paclitaxel derivative.
Rose WC; Lee FY; Golik J; Kadow J
Cancer Chemother Pharmacol; 2000; 46(3):246-50. PubMed ID: 11021743
[TBL] [Abstract][Full Text] [Related]
14. A novel taxane active against an orthotopically growing human glioma xenograft.
Laccabue D; Tortoreto M; Veneroni S; Perego P; Scanziani E; Zucchetti M; Zaffaroni M; D'Incalci M; Bombardelli E; Zunino F; Pratesi G
Cancer; 2001 Dec; 92(12):3085-92. PubMed ID: 11753988
[TBL] [Abstract][Full Text] [Related]
15. Anti-tumour activity of a panel of taxanes toward a cellular model of human cervical cancer.
Gallo D; Ferlini C; Distefano M; Cantelmo F; Gaggini C; Fattorossi A; Riva A; Bombardelli E; Proietti E; Mancuso S; Scambia G
Cancer Chemother Pharmacol; 2000; 45(2):127-32. PubMed ID: 10663627
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and toxicity profile of oral topotecan in a panel of human tumour xenografts.
De Cesare M; Zunino F; Pace S; Pisano C; Pratesi G
Eur J Cancer; 2000 Aug; 36(12):1558-64. PubMed ID: 10930804
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic measurements of IDN 5390 using electrospray ionization tandem mass spectrometry: structure characterization and quantification in dog plasma.
Song L; Prey JD; Xue J; Kanter P; Manzotti C; Bombardelli E; Morazzoni P; Pendyala L
Rapid Commun Mass Spectrom; 2005; 19(24):3617-25. PubMed ID: 16299696
[TBL] [Abstract][Full Text] [Related]
18. High-performance liquid chromatographic assay for the determination of the novel C-Seco-taxane derivative (IDN 5390) in mouse plasma.
Zaffaroni M; Frapolli R; Colombo T; Fruscio R; Bombardelli E; Morazzoni P; Riva A; D'Incalci M; Zucchetti M
J Chromatogr B Analyt Technol Biomed Life Sci; 2002 Nov; 780(1):93-8. PubMed ID: 12383484
[TBL] [Abstract][Full Text] [Related]
19. Medicinal chemistry and chemical biology of new generation taxane antitumor agents.
Ojima I; Geney R; Ungureanu IM; Li D
IUBMB Life; 2002; 53(4-5):269-74. PubMed ID: 12121008
[TBL] [Abstract][Full Text] [Related]
20. Risks and benefits of taxanes in breast and ovarian cancer.
Michaud LB; Valero V; Hortobagyi G
Drug Saf; 2000 Nov; 23(5):401-28. PubMed ID: 11085347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]